Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
企業コードCELZ
会社名Creative Medical Technology Holdings Inc
上場日May 01, 2009
最高経営責任者「CEO」Mr. Timothy Warbington
従業員数4
証券種類Ordinary Share
決算期末May 01
本社所在地211 E. Osborn Rd.
都市PHOENIX
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号85012
電話番号14803992822
ウェブサイトhttps://creativemedicaltechnology.com/
企業コードCELZ
上場日May 01, 2009
最高経営責任者「CEO」Mr. Timothy Warbington
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし